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Invasive aspergillosis is an uncommon infection in the immu-
nocompetent.1 Bevacizumab is a monoclonal antibody that
binds and inhibits vascular endothelial growth factor (VEGF)
preventing the formation of new blood vessels. Bevacizumab
has been shown to improve survival in metastatic colorectal
cancer when given in combination with chemotherapy.2 To
our knowledge infection is not described as a complication of
bevacizumab therapy.
We report herein a case of invasive aspergillosis occurring
during treatment with bevacizumab and suggest that the
possibility of a causal link deserves investigation.
A 54-year-old man was diagnosed with colonic cancer in
2005. He underwent right-sided hemicolectomy and was
given adjuvant chemotherapy with oxaliplatin, fluor-
ouracil and bevacizumab. He developed neutropenia on
two occasions, one month apart, following chemotherapy.
On both occasions the neutropenia was not profound
(absolute neutrophil count 0.76 and 0.37  109/l) and
recovered within one week (to 2.44 and 6.72  109/l,
respectively).
After his 11th cycle of chemotherapy he developed
fever, a dry cough and a new infiltrate on chest X-ray.
Computed tomography scanning of the chest showed a
cystic lesion. A transbronchial lung biopsy was undertaken
and this demonstrated fungal hyphae. Aspergillus fumiga-
tus was subsequently cultured. He was treated with intra-
venous amphotericin followed by oral itraconazole and
remains well.
In experimental models, Aspergillus species have been
shown to secrete angiogenesis inhibitors.3—5 In vivo these
may act to induce ischemia and prevent neutrophil mediated
clearance of the fungal infection. VEGF expression by macro-
phages is induced by hypoxia6 and lactate,7 and levels of
VEGF have been shown to be elevated in the presence of
aspergilloma.8 VEGF may therefore be an important element
in the host response to aspergillus infection.
In a trial examining the effect of bevacizumab on non-
small cell lung cancer, two patients from a total of 99
receiving bevacizumab developed aspergillosis compared
with none from 32 controls (OR 1.67, 95% CI 0.08—35.6).9
Chemotherapy-induced neutropenia is a risk factor for
invasive aspergillosis, however in this case neutropenia1201-9712/$32.00 # 2007 International Society for Infectious Diseases.was neither profound nor prolonged. Other potential risk
factors should be considered.
Identifying uncommon but serious side effects of new
drugs is difficult, and awareness of potential side effects is
crucial in encouraging reporting.
While bevacizumab might be promising as a new
adjuvant treatment modality for lung and colon cancer,
the incidence of invasive pulmonary aspergillosis with
potentially fatal consequences needs to be carefully
monitored.
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liver and bone involvement in a patient with
AIDS
A 39-year-old male who had emigrated from Malawi to the UK
presented to his general practitioner with an eight-week
history of an intermittent non-productive cough. He had
no hemoptysis or constitutional symptoms and was a non-
smoker. He reported having been hospitalized for twomonths
in Malawi for pulmonary Mycobacterium tuberculosis infec-
tion (PTB) eighteen years previously. He was referred to the
hospital outpatient clinic for further evaluation.
Examination findings included decreased air entry at the
left apex of the lung. A chest radiograph (CXR) showed left
apical opacification and cavitation with associated volume
loss (Figure 1). Sputum analysis for bacteria and acid-fast
bacilli (AFB) were negative on special staining and culture.
These findings were interpreted as representing previously
treated PTB infection. The patient consented to HIV testing
and was found to be HIV-1 antibody positive with a CD4 count
of 21  106 cells/l (2%) and HIV viral load of 233 000 copies/
ml. Co-infection with hepatitis B was confirmed by serology:
HBsAg positive and HBeAg positive. Co-trimoxazole was
started for Pneumocystis prophylaxis.
Four weeks later he re-presented to hospital with a one-
week history of severe frontal headache and general malaise,
but no fevers, photophobia or nuchal rigidity. Clinical exam-
ination was unremarkable except for the previously noted
findings in the left lung field. A serum cryptococcal latex
agglutination test (CrAg) was positive at a titer of 1:20.
Lumbar puncture evaluation revealed an opening pressure
of 18 cmH2O and microscopy confirmed the presence of
Cryptococcus on India ink staining, a white cell count
(WCC) of 2550 cells (95% mononuclear cells, 5% polymorphs)
and fewer than five red blood cells. Cerebrospinal fluid (CSF)
protein was 1266 mg/l (normal range 250—450 mg/l). The
CSF glucose:plasma glucose ratio was 1:2. CSF CrAg was
positive at a titer of 1:40. The patient was commenced on
intravenous amphotericin B and flucytosine. Cryptococcus
neoformans was cultured from the CSF. Abnormal results
were also obtained for: hemoglobin (Hb) 7.9 g/dl (normal
range 13.0—16.5 g/dl); mean cell volume (MCV) 75.5 fl (nor-
mal range 79—96.0 fl); WCC 3.95  109 cells/l (normal range
4.00—11.0  109 cells/l); and lymphocytes 0.85  109 cells/l
(normal range 1.30—4.00  109 cells/l). Neutrophils were
2.60  109 cells/l (normal range 2.50—7.50  109 cells/l).
During treatment for cryptococcal meningitis, the patient
complained of a productive cough of yellow sputum and
pleuritic chest pain. A repeat CXR revealed cavitation in
the apex of the left lung, unchanged from the investigationsof four weeks previously. A fibreoptic bronchoscopy was
normal and staining and cultures of bronchoalveolar lavage
(BAL) fluid were negative for bacteria, Pneumocystis jirovecii
(Pneumocystis pneumonia, PCP) and mycobacteria. Six
further sputum samples were negative for bacteria and
mycobacteria on stain and culture. A course of oral co-
amoxiclav was prescribed for a presumed bacterial chest
infection, which resulted in an improvement in his respira-
tory symptoms. Prior to discharge the patient was converted
to oral fluconazole 400 mg daily. Two weeks following dis-
charge he was clinically well and commenced on anti-retro-
viral therapy consisting of zidovudine, lamivudine and
efavirenz.
Five months after diagnosis of cryptococcal meningitis the
patient presented with a productive cough and pleuritic
chest pain localized to the left apex. He denied any hemop-
tysis. On examination he was afebrile and decreased air entry
was again noted in the left upper lobe. Investigations showed
a WCC 3.72  109 cells/l, Hb 9.3 g/dl, MCV 87.9 fl, platelets
573  109/l (normal range 150—450  109/l), neutrophils
1.98  109 cells/l, and lymphocytes 0.65  109 cells/l. C-
Reactive protein (CRP) was elevated at 192.1 mg/l (normal
